Plexium

Plexium is a next-generation targeted protein degradation startup that was founded in 2018. Positioned as the premier company in this field, Plexium aims to discover a wide range of monovalent target protein degraders that overcome the limitations of PROTACs and cereblon. The company's platform is a proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. Plexium is focusing on advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Their vision is encapsulated in their slogan, "Pushing the Boundaries of Targeted Protein Degradation to Improve Lives". Notably, the startup received a significant Series B investment of $102.00M on 23 February 2022, demonstrating high investor confidence. The investors in this round include CRV, Lux Capital, Neotribe Ventures, RA Capital Management, Pivotal bioVenture Partners, Pappas Capital, MERL Ventures Fund, SoftBank Vision Fund, DCVC Bio, and Surveyor Capital. The industries Plexium operates in are Biotechnology, Health Care, and Pharmaceutical, with its headquarters located in the United States. Overall, Plexium has drawn attention and significant investment due to its innovative approach in the field of targeted protein degradation, and with the backing of prominent investors, it has positioned itself as a key player in the biotech and pharmaceutical spaces.